Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in AML and MDS in First Complete Remission
NCT00045396Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started Jun 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00045396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045396.